Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

Exclusion Criteria

• •Pathologic evidence of pancreatic cancer
• •Pregnant or breast-feeding patients
• •Refusal or inability to tolerate scan (eg anxiety or claustrophobia)
• •Inability to lay flat or meet the standard requirements of traditional MRI
• •Hepatic function from assays obtained within 6 weeks prior to the study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay
• •1. Bilirubin \> 1.5 x ULN
• •2. AST/ALT \> 2.5 x ULN
• •3. Albumin \< 3 g/dL
• •4. GGT \> 2.5 x ULN if Alkaline Phosphatase \> 2.5 x ULN
• •Renal function with Creatinine \> 1.5 x ULN or creatinine clearance \< 60 mL/min, from assays obtained within 6 weeks prior to study enrollment
• •Cardiac: congestive heart failure with New York Heart Association (NYHA) status ≥2, poorly controlled hypertension, a history of clinically significant EKG abnormalities, or myocardial infarction within 6 months of study enrollment.